According to the Zhitong Finance App, Lai Kai Pharmaceutical-B (02105.HK) announced that the Group has initiated the recruitment of subjects for the LAE118 Phase I clinical study (“Phase I Clinical Study”) for the treatment of advanced solid tumors in China, and has completed the enrollment of the first test subjects.

According to the Zhitong Finance App, Lai Kai Pharmaceutical-B (02105.HK) announced that the Group has initiated the recruitment of subjects for the LAE118 Phase I clinical study (“Phase I Clinical Study”) for the treatment of advanced solid tumors in China, and has completed the enrollment of the first test subjects.